MiMedx GroupMDXG -0.39%57 Median PS Value is $6.99 as of Jun. 26, 2026, which is 992% above its 10-year median of 0.64. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 276 Biotechnology companies, MiMedx Group ranks better than 57.25% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. MiMedx Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.603. MiMedx Group's 10-Year median PS Ratio is 2.6854. Therefore, the Median PS Value for today is $6.99.
As of today (2026-06-26), MiMedx Group's share price is $3.815. MiMedx Group's Median PS Value is $6.99. Therefore, MiMedx Group's Price to Median PS Value for today is 0.55.
The historical rank and industry rank for MiMedx Group's Median PS Value or its related term are showing as below:
MDXG'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15 Med: 0.64 Max: 1.37
Current: 0.55
During the past 13 years, the highest Price to Median PS Value of MiMedx Group was 1.37. The lowest was 0.15. And the median was 0.64.
MDXG's Price-to-Median-PS-Value is ranked better than 57.25% of 276
companies
in the Biotechnology industry
Industry Median: 0.62
vs MDXG: 0.55
MiMedx Group (NAS:MDXG) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
MiMedx Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.815
/
6.99
=
0.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group Median PS Value Related Terms
MiMedx Group Median PS Value Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXG vs ASMB, AGMB, TRAX: Median PS Value Comparison
For the Biotechnology subindustry, MiMedx Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.6854.
MiMedx Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.603.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a Median PS Value of $6.99 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on MiMedx Group and its competitors. This is 992% above median its historical median of 0.64. Over the past decade, MiMedx Group's Median PS Value has ranged from 0.15 to 1.37. According to the industry distribution chart, MiMedx Group ranks #118 out of 276 companies in the Biotechnology industry, placing it in the top 42.8%.
Is MiMedx Group's Median PS Value too high?
MiMedx Group's current Median PS Value of $6.99 is 992% above median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 1.37. The Biotechnology industry median Median PS Value is 0.62. MiMedx Group's value of $6.99 is 1027.4% above this industry median. Based on the distribution chart, MiMedx Group ranks #118 out of 276 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Median PS Value compare to ASMB and AGMB?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #118 out of 276 companies for Median PS Value. This puts MiMedx Group in the upper half of its industry. The industry median Median PS Value is 0.62. MiMedx Group's value of $6.99 is 1027.4% above this benchmark. Historically, MiMedx Group's own Median PS Value has ranged from 0.15 to 1.37 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 0.62, MiMedx Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Median PS Value of $6.99 is 1027.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Median PS Value is $6.99, which is 992% above median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.82 — trading 45.2% below its estimated fair value. The current Median PS Value is $6.99, which is 992% above median its 10-year median of 0.64 and 1027.4% above the Biotechnology industry median of 0.62. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Median PS Value is $6.99 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.82 is trading 45.2% below its estimated GF Value™ of $6.96.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Median PS Value: $6.99 (992% above median its 10-year median of 0.64)
GF Value™: $6.96 vs. price of $3.82 (45.2% below fair value)
Industry Position: 1027.4% above the Biotechnology median (#118 of 276)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
